^
Association details:
| Biomarker: | COL4A5 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma
Published date:
12/13/2022
Excerpt:
Spearman correlation analysis of the 12 pyroptosis-related genes and 135 chemotherapeutic drugs in the Genomics of Drug Sensitivity in Cancer database revealed that the expression of the solute carrier family 31 member 2 (SLC31A2) and collagen type 4 alpha 5 chain (COL4A5) was related to the resistance to most chemotherapies (Fig. 6C). The cell counting Kit-8 (CCK-8; Sigma-Aldrich, Shanghai, China) assay demonstrated that SLC31A2 and COL4A5 are tightly associated with vemurafenib-resistance.
DOI:
10.1038/s41598-022-24879-y
